Clalit Health Services (CHS), Israel’s largest state-mandated healthcare provider, has reported a 94% decrease in symptomatic infections of Coronavirus among 600,000 people who were administered two doses of Pfizer’s vaccine during the country’s biggest COVID-19 vaccine study.
CHS, which covers more than 50% of the Israeli citizens, noted that the study’s participants were 92% less likely to experience severe illness from the Coronavirus.
A statement from the CHS states that the comparison of the Pfizer group was done with a group of the same size, with matching medical histories, who had not received the vaccine.
Chief Innovation Officer (CIO) at CHS, Ran Balicer, has said that Pfizer’s Coronavirus vaccine, which was developed in collaboration with BioNTech, is extremely effective one week after the second dose.
He added that the effectiveness of Pfizer’s Coronavirus increases further two weeks after the second dose.
Weizmann Institute of Science (WIS), an Israeli public research university that has been maintaining the country’s Coronavirus data, has also observed a sharp decrease in the rate of hospitalization and serious illness among the first age group to be vaccinated, aged 60 or more, for the first time since the start of Coronavirus outbreak in the country.